These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Effect of angiotensin II type-1 receptor blockers on stable allograft kidneys: prospective randomized study.
    Author: Nouri-Majalan N, Ghafari A, Moghaddasi S.
    Journal: Transplant Proc; 2009 Sep; 41(7):2832-4. PubMed ID: 19765449.
    Abstract:
    OBJECTIVE: Is assess the effects of angiotensin II type-I receptor blockers on outcomes in renal transplant recipients without proteinuria or posttransplantation erythrocytosis. PATIENTS AND METHODS: Fifty renal transplant recipients (30 men and 20 women, with a mean [SD] age of 40 [13] years) were randomized into 2 groups of 25 patients each; 1 group was treated with losartan for 1 year, and the other was not (control group). Blood pressure and other biochemical parameters were measured at baseline and at 6 and 12 months posttransplantation. RESULTS: After 1 year, the losartan group had significantly lower systolic blood pressure (113 [22] mm Hg vs 126 [18] mm Hg; P = .04) and hemoglobin concentration (12.8 [1.9] g/dL vs 14.5 [2.1] g/dL; P = .006) and significantly higher serum high-density lipoprotein cholesterol concentration (58 [22] mg/dL vs 47 [10] mg/dL; P = .03) compared with the control group; however the incidence of anemia did not differ (37% vs 20%; P = .20). In the losartan group, there were significant changes in hemoglobin concentration between baseline and 6 months (14.5 [1.6] g/dL vs 12.9 [1.49] g/dL; P < .001), but not between 6 and 12 months (12.9 [1.49] g/dL vs 12.8 [1.96] g/dL; P = .43). After 1 year, there were no significant between-group differences in diastolic hypertension, serum creatinine concentration, creatinine clearance, and serum potassium, low-density lipoprotein cholesterol, triglyceride, and uric acid concentrations. CONCLUSION: Losartan significantly increased high-density lipoprotein concentration and significantly decreased systolic hypertension. Although losartan decreased the hemoglobin concentration during the first 6 months, its effect did not progress with longer use. To determine the effect of losartan on renal function, additional studies with longer follow-up are needed.
    [Abstract] [Full Text] [Related] [New Search]